Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $0.0.

  • Xeris Biopharma Holdings' EPS (Basic) rose 10344.97% to $0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.1, marking a year-over-year increase of 7727.27%. This contributed to the annual value of -$0.37 for FY2024, which is 1697.52% up from last year.
  • Xeris Biopharma Holdings' EPS (Basic) amounted to $0.0 in Q3 2025, which was up 10344.97% from -$0.01 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' EPS (Basic) registered a high of $0.0 during Q3 2025, and its lowest value of -$0.44 during Q4 2021.
  • Its 5-year average for EPS (Basic) is -$0.16, with a median of -$0.12 in 2023.
  • In the last 5 years, Xeris Biopharma Holdings' EPS (Basic) tumbled by 2222.22% in 2024 and then surged by 10344.97% in 2025.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' EPS (Basic) stood at -$0.44 in 2021, then soared by 77.27% to -$0.1 in 2022, then grew by 10.0% to -$0.09 in 2023, then skyrocketed by 61.29% to -$0.03 in 2024, then skyrocketed by 110.89% to $0.0 in 2025.
  • Its EPS (Basic) was $0.0 in Q3 2025, compared to -$0.01 in Q2 2025 and -$0.06 in Q1 2025.